Jaka jest cena za Aardvark Therapeutics, Inc. Common Stock (AARD)

Cena za Aardvark Therapeutics, Inc. Common Stock (AARD) wynosi $7.22

Jaka jest kapitalizacja rynkowa dla Aardvark Therapeutics, Inc. Common Stock (AARD)

Kapitalizacja rynkowa dla Aardvark Therapeutics, Inc. Common Stock (AARD) wynosi $158.03M

Aardvark Therapeutics, Inc. Common Stock (AARD) Historia Cen

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Rok	Wydajność
2026 (TTM)	-33.51%
2025	0.00%

Rok

Wydajność

2026 (TTM)

-33.51%

2025

0.00%

Firma	Cena akcji	Zmiana 1r%	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$553.09	42.85%	US
Argenx SE ARGX.US	$1.02K	44.02%	NL
Moderna, Inc. MRNA.US	$158.64	541.49%	US
CSL Limited CSL.AX	$122.16	-12.60%	AU
Lonza Group AG LONN.SW	$772.27	7.33%	CH

Firma

Cena akcji

Zmiana 1r%

Kraj